Mast cell leukemia classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2],Sogand Goudarzi, MD [3]

Overview

Mast cell leukemia may be classified into two categories based on prognosis to leukemic and aleukemic. Also, it can be classified to acute or chronic according to the duration of the symptoms.

Classification

In 2016 the World Health Organization (WHO) changed classification of tumors of hematopoietic and lymphoid tissues.Based on the duration of symptoms, mast cell leukemia may be classified into either acute or chronic.^[1]^[2]^[3]
In the current classification mastocytosis is a major category. In the last classification mastocytosis was subtype of major category (myeloproliferative neoplasms).^[2]

1.Cutaneous mastocytosis (CM)

2.Systemic mastocytosis

Indolent systemic mastocytosis (ISM)
Smoldering systemic mastocytosis (SSM)
Systemic mastocytosis with an associated hematological neoplasm (SM-AHN)
Aggressive systemic mastocytosis (ASM)
Mast cell leukaemia (MCL)

3.Mast cell sarcoma (MCS)

Mast cell leukemia may be classified into two categories based on prognosis:^[3]

Leukemic variant

Circulating mast cells ≥ 10%
Bone marrow mast cells ≥ 20%

Aleukemic variant

Circulating mast cells < 10%

Based on the duration of symptoms, mast cell leukemia may be classified into:^[1]

Acute mast cell leukemia
Chronic mast cell leukemia

References

↑ ^1.0 ^1.1 Savini, P.; Rondoni, M.; Poletti, G.; Lanzi, A.; Quercia, O.; Soverini, S.; De Benedittis, C.; Musardo, G.; Martinelli, G.; Stefanini, G. F. (2015). “Serum Total Tryptase Level Confirms Itself as a More Reliable Marker of Mast Cells Burden in Mast Cell Leukaemia (Aleukaemic Variant)”. Case Reports in Hematology. 2015: 1–4. doi:10.1155/2015/737302. ISSN 2090-6560.
↑ ^2.0 ^2.1 Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). “The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia”. Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.
↑ ^3.0 ^3.1 Georgin-Lavialle, S.; Lhermitte, L.; Dubreuil, P.; Chandesris, M.-O.; Hermine, O.; Damaj, G. (2012). “Mast cell leukemia”. Blood. 121 (8): 1285–1295. doi:10.1182/blood-2012-07-442400. ISSN 0006-4971.

Template:WikiDoc Sources

[SaviniRondoni2015-1] 1.0 ^1.1 Savini, P.; Rondoni, M.; Poletti, G.; Lanzi, A.; Quercia, O.; Soverini, S.; De Benedittis, C.; Musardo, G.; Martinelli, G.; Stefanini, G. F. (2015). “Serum Total Tryptase Level Confirms Itself as a More Reliable Marker of Mast Cells Burden in Mast Cell Leukaemia (Aleukaemic Variant)”. Case Reports in Hematology. 2015: 1–4. doi:10.1155/2015/737302. ISSN 2090-6560.

[ArberOrazi2016-2] 2.0 ^2.1 Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). “The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia”. Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.

[Georgin-LavialleLhermitte2012-3] 3.0 ^3.1 Georgin-Lavialle, S.; Lhermitte, L.; Dubreuil, P.; Chandesris, M.-O.; Hermine, O.; Damaj, G. (2012). “Mast cell leukemia”. Blood. 121 (8): 1285–1295. doi:10.1182/blood-2012-07-442400. ISSN 0006-4971.

[1]

[2]

[3]